What topics does this cannabis study cover?

This study covers research on: CBD, Neuroprotection, Inflammation.

CBD Neuroprotection Inflammation

Nanotech innovations promise to unlock CBD's medical potential

Q: Where was this research published?

Published in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie on May 11, 2026.

Unraveling approaches for cannabidiol delivery nanosystems: A patent review.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie • May 11, 2026 • Review • Moderately Relevant

🤖

AI Summary

This comprehensive patent review examines the latest nanotechnology innovations designed to solve a major challenge in CBD therapy: poor water solubility and limited bioavailability. Researchers analyzed 538 patent documents filed with major patent offices over the past decade, identifying 16 key technologies including nanoemulsions, microemulsions, polymeric nanoparticles, liposomes, and nanocrystals. These advanced delivery systems represent a significant technological shift in how cannabidiol can be formulated for medical use, with the United States leading innovation in this space, particularly peaking in 2020.

The identified nanotechnologies target practical applications in anti-inflammatory, neurological, and antimicrobial treatments—areas where CBD has shown promise in earlier research. By dramatically improving how the body absorbs and distributes cannabidiol, these nano-delivery systems could make CBD-based medicines more effective at lower doses and with better consistency. However, the review makes an important distinction: patent filings represent technological potential rather than proven medicine. These innovations describe promising formulations but lack the rigorous clinical testing required for regulatory approval and widespread medical use.

The research highlights both the exciting progress and the critical gap in cannabis nanomedicine development. While nanotechnology offers genuine solutions to CBD's bioavailability problems, the authors emphasize that substantial preclinical and clinical studies remain necessary before these patented systems can become approved therapeutics. This review essentially maps the frontier of CBD drug delivery innovation and signals that the next phase must be rigorous validation—transforming laboratory patents into clinically proven treatments that could expand therapeutic options for patients with inflammatory, neurological, and infectious diseases.

📄 Original Abstract

Cannabidiol (CBD), a non-psychoactive phytocannabinoid from Cannabis sativa, exhibits well-documented biological activities, including anti-inflammatory, antiepileptic, and antioxidant effects. However, its poor aqueous solubility and limited bioavailability significantly hinder its clinical application. This integrative review aimed to analyze recent patented nanotechnologies developed to improve CBD delivery and address its biopharmaceutical limitations. Patent documents filed over the last 10 years in the European Patent Office (EPO) and the World Intellectual Property Organization (WIPO) were systematically screened within an integrative review framework. This approach was designed as a qualitative, exploratory technological analysis, rather than a systematic or exhaustive patent landscape study. Trends were analyzed descriptively by filing year and geographic origin. Formulation strategies, physicochemical characteristics, and applicant-reported applications were qualitatively evaluated. A total of 538 documents were identified, of which 16 met the inclusion criteria. The United States was the leading country in patent filings, with a peak observed in 2020. The identified technologies included nanoemulsions, microemulsions, polymeric and lipid nanoparticles, liposomes, nanocrystals, and nanofibers. Reported applications suggest potential use in anti-inflammatory, neurological, and antimicrobial contexts. Patented nanocarriers demonstrate potential to improve CBD delivery and stability. However, these findings should be interpreted as technological propositions rather than validated pharmacological evidence, since patent disclosures do not necessarily include peer-reviewed experimental validation. Further preclinical and clinical studies are required to confirm therapeutic performance, ensure safety, and support regulatory translation. Continued advances in nanosystem design may contribute to the future development of cannabinoid-based nanomedicines.

Paper Type

📚 Review

Publication

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: May 11, 2026
PMID: 42116250
DOI: 10.1016/j.biopha.2026.119509

Authors (7)

D T Freire Pharmacy Department, Dispersed Systems Laboratory (LaSiD), Federal University of Rio Grande do Norte, UFRN, Natal, RN 59010-180, Brazil; College of Pharmaceutical Sciences, Food and Nutrition, Laboratory of Micro and Nanostructured Systems (LASMINano), Federal University of Mato Grosso do Sul (UFMS), Campo Grande, MS 79070-900, Brazil.
D Dourado Pharmacy Department, Dispersed Systems Laboratory (LaSiD), Federal University of Rio Grande do Norte, UFRN, Natal, RN 59010-180, Brazil.
J A Miranda Pharmacy Department, Dispersed Systems Laboratory (LaSiD), Federal University of Rio Grande do Norte, UFRN, Natal, RN 59010-180, Brazil; College of Pharmaceutical Sciences, Food and Nutrition, Laboratory of Micro and Nanostructured Systems (LASMINano), Federal University of Mato Grosso do Sul (UFMS), Campo Grande, MS 79070-900, Brazil.
D T Pereira Pharmacy Department, Dispersed Systems Laboratory (LaSiD), Federal University of Rio Grande do Norte, UFRN, Natal, RN 59010-180, Brazil.
D P Freire College of Pharmaceutical Sciences, Food and Nutrition, Laboratory of Micro and Nanostructured Systems (LASMINano), Federal University of Mato Grosso do Sul (UFMS), Campo Grande, MS 79070-900, Brazil.
+2 more authors